Tvardi Therapeutics Reports Positive Interim Phase 2 HCC Data and Encouraging IPF Post-Hoc Analysis
Summary
Tvardi Therapeutics provided an updated corporate presentation detailing positive interim Phase 1b/2 results for TTI-101 in hepatocellular carcinoma (HCC) and encouraging post-hoc analysis from its TTI-101 idiopathic pulmonary fibrosis (IPF) trial, alongside updates on its TTI-109 prodrug.
Key Events
-
Positive Interim HCC Data
The TTI-101 Phase 1b/2 trial in hepatocellular carcinoma (HCC) demonstrated a 92% disease control rate and 33% objective response rate, which compares favorably to third-party trials.
-
Encouraging IPF Post-Hoc Analysis
A post-hoc analysis of the TTI-101 idiopathic pulmonary fibrosis (IPF) trial indicated greater declines in fibrosis score and IL-6 levels, and an increase in FVC among treated patients, despite initial trial challenges.
-
TTI-109 Prodrug Advancement
The company is progressing TTI-109, a prodrug designed to enhance TTI-101 delivery, with Phase 1 healthy volunteer data anticipated in the first half of 2026.
-
Cash Runway Update
Tvardi Therapeutics reported $36.5 million in cash and equivalents as of September 30, 2025, providing an anticipated cash runway into Q4 2026.
Analysis
The updated corporate presentation highlights significant progress in Tvardi's clinical pipeline. The interim Phase 1b/2 data for TTI-101 in hepatocellular carcinoma (HCC) shows a high disease control rate (92%) and objective response rate (33%), which compares favorably to existing therapies and suggests strong potential in an area of high unmet need. While the initial TTI-101 idiopathic pulmonary fibrosis (IPF) trial faced challenges, the detailed post-hoc analysis revealed positive trends in fibrosis reduction, IL-6 decline, and FVC improvement, indicating a potential therapeutic effect. These clinical advancements, particularly the promising HCC data, are crucial for a micro-cap biotech and could significantly impact the company's valuation and future development strategy. Investors should monitor the upcoming topline results for the Phase 2 HCC trial in 1H 2026.
At the time of this filing, TVRD was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.4M. The 52-week trading range was $3.74 to $43.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.